[Expert consensus on the use of pegylated recombinant human granulocyte colony-stimulating factor in the treatment of hematologic malignancies (2026 edition)].
1/5 보강
Neutropenia is one of the most common hematologic toxicities during the treatment of hematologic malignancies.
APA
(2026). [Expert consensus on the use of pegylated recombinant human granulocyte colony-stimulating factor in the treatment of hematologic malignancies (2026 edition)].. Zhonghua yi xue za zhi, 106(1), 39-48. https://doi.org/10.3760/cma.j.cn112137-20250828-02222
MLA
. "[Expert consensus on the use of pegylated recombinant human granulocyte colony-stimulating factor in the treatment of hematologic malignancies (2026 edition)].." Zhonghua yi xue za zhi, vol. 106, no. 1, 2026, pp. 39-48.
PMID
41285416 ↗
Abstract 한글 요약
Neutropenia is one of the most common hematologic toxicities during the treatment of hematologic malignancies. It can lead to delays in subsequent treatments, dose reduction of chemotherapeutic agents, or even treatment discontinuation. Furthermore, neutropenia increases the risk of febrile neutropenia and severe infections, which adversely affect patient prognosis. Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is effective in preventing and treating neutropenia, and is widely used in the treatment of hematologic malignancies and hematopoietic stem cell transplantation (HSCT). To further promote the standardized application of PEG-rhG-CSF in hematological malignancies, the Hematology Oncology Committee of China Anti-Cancer Association organized domestic experts in the related fields, based on current evidence-based medical data and clinical practice, to focus on the clinical application of PEG-rhG-CSF in hematologic malignancies, hematopoietic stem cell mobilization and hematopoietic function reconstitution after HSCT. Eight recommendation opinions were finally proposed to guide the standardized use of drugs in clinical practice.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.